What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Enveda Biosciences
Translates nature's chemistry into small-molecule therapeutics using AI and metabolomics.
What they do
Enveda Biosciences uses metabolomics and machine learning to map the chemical diversity of plants. By identifying and isolating active small molecules from natural sources, the company creates a proprietary library of novel drug candidates for pharmaceutical development targeting inflammatory and metabolic diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Natural product discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Boulder, USA
- Region
- North America
- Founded
- 2019
- Total funding
- $230M raised
Notable investors: Kinnevik, F-Prime Capital, True Ventures, Premji Invest.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
The AAV9 CNS Blueprint: Inside Ultragenyx's Landmark Fayuvi Approval
Dr. Dereck Mush, MD, MBA